EMA Withdrawn: Pregabalin Sandoz GmbH (pregabalin) — Sandoz GmbH

View source ↗

Summary

The EMA withdrew the Pregabalin Sandoz GmbH (pregabalin) product from the market, affecting indications in Anxiety Disorders and Epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Epilepsy

Drugs mentioned

• Pregabalin Sandoz GmbH (pregabalin)

Snippet

Status: Withdrawn. Therapeutic area: Anxiety Disorders;Epilepsy. MAH: Sandoz GmbH. Decision date: 21/09/2023